Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1635088 · FYE Mar 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $32.87Day −2.87%Mkt cap $23.6B1Y +187.8%Off 52W high −11.2%Vol (1Y) 42.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,204 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest5.1% of sh out |
| Days to cover7.7d |
| 13F net flow (QoQ)+2.68% |
| Top-10 13F concentration57.0% |
| Next report (est.)2026-08-19 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$8.3M |
| Earnings (TTM)-$299.8M |
| ROE−6.5% |
| Net margin−3629.2% |
| ROIC−12.8% |
| Sales growth 3Y−36.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+51.5% |
| 1Y+187.8% |
| 3Y+174.4% |
| Since incept. (ann.)+33.7% |
Total return through 2026-07-29 · series begins 2021-10-04. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)42.1% |
| Ann. volatility (3Y)40.9% |
| Sharpe (1Y)2.78 |
| Sharpe (3Y)1.05 |
| Max drawdown (1Y)−12.8% |
| Max drawdown (3Y)−36.5% |
| Beta (3Y vs SPY)0.72 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 78.0M | $2.2B | 10.84% | +18.5% |
| MORGAN STANLEY | 51.8M | $1.4B | 7.21% | −11.2% |
| BlackRock, Inc. | 44.3M | $1.2B | 6.15% | +7.5% |
| QVT Financial LP | 25.2M | $697M | 3.50% | −4.6% |
| UBS Group AG | 22.6M | $627M | 3.14% | +23.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 20.7M | $573M | 2.88% | new |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 19.8M | $550M | 2.76% | new |
| STATE STREET CORP | 16.2M | $448M | 2.25% | −6.8% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-20 | — | — | $2.5M | −66.7% |
| 2025-12-31 | 2026-02-06 | −$0.38 | −265.2% | $2.0M | −77.8% |
| 2025-09-30 | 2025-11-10 | −$0.17 | — | $1.6M | −64.9% |
| 2025-06-30 | 2025-08-11 | −$0.33 | −375.0% | $2.2M | −72.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-19 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
